Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$50.22 ▼ -0.12
(-0.24%)
MKT CAP: $10.37B • VOL: 4.17M
52W L $33 52W H $58
QGEN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.09B | $1.98B | $1.97B |
| YoY Revenue Growth % | +5.7% | +0.7% | — |
| Gross Profit | $1.30B | $967.4M | — |
| Gross Margin % | 62.2% | 48.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $465.9M | $97.7M | $409.9M |
| Operating Margin % | 22.3% | 4.9% | 20.9% |
| Net Income (GAAP) | $424.9M | $83.6M | $341.3M |
| EBITDA (Normalized) | $626.7M | $231.5M | $480.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $654.3M | $673.6M | $459.5M |
| Capital Expenditures (CapEx) | $201.0M | $167.2M | $88.4M |
| Free Cash Flow (FCF) | $453.3M | $506.4M | $371.0M |
| FCF Margin % | 21.7% | 25.6% | 18.9% |
| Return on Invested Capital (ROIC %) | 8.0% | 2.1% | 9.4% |
| Cash & Short-Term Equivalents | $839.0M | $663.6M | — |
| Total Debt (Short + Long Term) | $1.65B | $839.7M | $1.34B |
| Total Stockholders' Equity | $3.78B | $3.57B | $2.74B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QGEN.